Published in Telemedicine Business Week, September 22nd, 2004
The new data are to include an out-of-vial option for testing for the presence of high risk HPV DNA with the Digene hc2 High-Risk HPV DNA Test, using the same specimen collected to prepare SurePath slides for cytological analysis.
In a supplemental filing to its premarket approval (PMA) for the SurePath liquid-based Pap test, TriPath Imaging submitted data from a prospective, paired sample clinical study designed to validate the testing of cervical specimens collected...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Business Week